Seminars in dialysis
-
Seminars in dialysis · Jul 2014
ReviewGuidelines for reporting case studies on extracorporeal treatments in poisonings: methodology.
A literature review performed by the EXtracorporeal TReatments In Poisoning (EXTRIP) workgroup highlighted deficiencies in the existing literature, especially the reporting of case studies. Although general reporting guidelines exist for case studies, there are none in the specific field of extracorporeal treatments in toxicology. Our goal was to construct and propose a checklist that systematically outlines the minimum essential items to be reported in a case study of poisoned patients undergoing extracorporeal treatments. ⋯ The final checklist consists of 114 items considered essential for case study reporting. This methodology of alternate voting and external validation rounds was useful in developing the first reporting guideline for case studies in the field of extracorporeal treatments in poisoning. We believe that this guideline will improve the completeness and transparency of published case reports and that the systematic aggregation of information from case reports may provide early signals of effectiveness and/or harm, thereby improving healthcare decision-making.
-
Seminars in dialysis · May 2014
Randomized Controlled Trial Multicenter Study Comparative StudyA comparison between the HeRO graft and conventional arteriovenous grafts in hemodialysis patients.
Venous stenosis and occlusion are a major cause of vascular access dysfunction and failure. The HeRO Graft bypasses occlusion and traverses stenosis with outflow directly into the central venous circulation. A randomized, multicenter study was conducted to evaluate the efficacy and safety of the HeRO Graft relative to conventional AV grafts. ⋯ The rates of intervention were 2.2/year for HeRO Graft and 1.6/year for the control (p = 0.100). Median days to loss of secondary patency was 238 for HeRO Graft versus 102 for the control (p = 0.032). The HeRO Graft appears to provide similar patency, adequacy of dialysis, and bacteremia rates to those of conventional AV grafts.
-
Seminars in dialysis · May 2014
Case ReportsHemodialysis for the treatment of severe accidental hypothermia.
Severe hypothermia is defined as a core body temperature <28°C and is associated with in-hospital mortality rates of 50% or higher. Delays in rewarming and slower rates of rewarming are the most important prognostic factors associated with increased mortality. Arrhythmias are the most common cause of mortality in patients with severe accidental hypothermia. ⋯ We describe a case where hemodialysis (HD) was used to treat accidental hypothermia in a patient with an initial temperature of 23.5°C. Average rewarming rates of 1.5°C/hour were achieved. The advantages of HD when compared with CBP are that it is (1) more widely and readily available, (2) less invasive, (3) less expensive, and (4) can correct associated acidosis and electrolyte abnormalities commonly seen in patients with severe hypothermia.
-
Diabetes mellitus is the leading cause of end-stage renal disease (ESRD) in the U. S. and many countries globally. The role of improved glycemic control in ameliorating the exceedingly high mortality risk of diabetic dialysis patients is unclear. ⋯ Similar to more recent approaches in the general population, there is concern that glucose normalization may be harmful in ESRD patients. There is uncertainty surrounding the optimal glycemic target in this population, although recent epidemiologic data suggest that HbA1c ranges of 6% to 8%, as well as 7% to 9%, are associated with increased survival rates among diabetic dialysis patients. Lastly, many glucose-lowering drugs and their active metabolites are renally metabolized and excreted, and hence, require dose adjustment or avoidance in dialysis patients.